Contributions
Abstract: P386
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: The assessment and tracking of symptoms is important for multiple sclerosis (MS) management. Current validated measurements of a single symptom often require multiple items, creating a significant high burden for patients when multiple symptoms are being assessed.
Objective: We developed a tool where patients rated the severity of 13 common symptoms on a numeric rating scale from 0-10. The aim was to validate six of the symptoms against commonly used scales (including walking difficulties, fatigue, pain, feelings of anxiety, depression and vision problems).
Method: Data were collected through the Australian MS Longitudinal Study (2015 Medical Survey: n=1,985; 2016 Baseline Economic Impact Survey, n=1,577). Validation measures included Patient Determined Disease Steps Scale (PDDS), Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), Assessment of Quality of Life (AQoL) (with sub-scores for mobility, fatigue, pain, anxiety, depression and vision problems), and European Quality of Life (EQ-5D) (with sub-scores for mobility, pain, anxiety/depression). Concurrent validity was assessed using Spearman rank correlations. Predictive validity was assessed by comparing the R-squared or pseudo R-squared from regression models.
Results: We observed a high correlation between walking difficulties and PDDS (r=0.82), a good correlation between fatigue and FSS (r=0.72), pain and AQoL-pain (r=0.77), feelings of anxiety with HADS-Anxiety (r=0.68), and feelings of depression with HADS-Depression (r=0.63), and a fair agreement between vision problems and AQoL-vision (r=0.43). In terms of predictive validity, the R-squared (or pseudo R-squared) of associations with quality of life or work productivity were generally similar for our symptom severity assessment compared to the comparison measures. For example, the PDDS explained 23% of the variability of AQol, and our walking difficulties assessment explained 24% of the variability.
Conclusions: The assessment of self-reported MS symptom severity using single-item 0-10 numeric rating scales seems to have adequate concurrent and predictive validity.
Disclosure: Yan Zhang: nothing to disclose
Steve Simpson: nothing to disclose
Bruce Taylor: nothing to disclose
Ingrid van der Mei: nothing to disclose
Abstract: P386
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: The assessment and tracking of symptoms is important for multiple sclerosis (MS) management. Current validated measurements of a single symptom often require multiple items, creating a significant high burden for patients when multiple symptoms are being assessed.
Objective: We developed a tool where patients rated the severity of 13 common symptoms on a numeric rating scale from 0-10. The aim was to validate six of the symptoms against commonly used scales (including walking difficulties, fatigue, pain, feelings of anxiety, depression and vision problems).
Method: Data were collected through the Australian MS Longitudinal Study (2015 Medical Survey: n=1,985; 2016 Baseline Economic Impact Survey, n=1,577). Validation measures included Patient Determined Disease Steps Scale (PDDS), Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), Assessment of Quality of Life (AQoL) (with sub-scores for mobility, fatigue, pain, anxiety, depression and vision problems), and European Quality of Life (EQ-5D) (with sub-scores for mobility, pain, anxiety/depression). Concurrent validity was assessed using Spearman rank correlations. Predictive validity was assessed by comparing the R-squared or pseudo R-squared from regression models.
Results: We observed a high correlation between walking difficulties and PDDS (r=0.82), a good correlation between fatigue and FSS (r=0.72), pain and AQoL-pain (r=0.77), feelings of anxiety with HADS-Anxiety (r=0.68), and feelings of depression with HADS-Depression (r=0.63), and a fair agreement between vision problems and AQoL-vision (r=0.43). In terms of predictive validity, the R-squared (or pseudo R-squared) of associations with quality of life or work productivity were generally similar for our symptom severity assessment compared to the comparison measures. For example, the PDDS explained 23% of the variability of AQol, and our walking difficulties assessment explained 24% of the variability.
Conclusions: The assessment of self-reported MS symptom severity using single-item 0-10 numeric rating scales seems to have adequate concurrent and predictive validity.
Disclosure: Yan Zhang: nothing to disclose
Steve Simpson: nothing to disclose
Bruce Taylor: nothing to disclose
Ingrid van der Mei: nothing to disclose